<DOC>
	<DOCNO>NCT01710020</DOCNO>
	<brief_summary>There 2 study period study . In Period 1 , CP-690,550 administer approximately 1 2 hour follow hemodialysis . If significant non-renal clearance drug occur dialyzability CP-690,550 could assess Period 1 , second period ( Period 2 ) conduct . In Period 2 , single dose drug administer approximately 4 hour prior hemodialysis .</brief_summary>
	<brief_title>Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects endstage renal disease Subjects need hemodialysis 3 time weekly Subjects evidence history clinically significant disease , exclude common subject EndStage Renal Disease ( ESRD ) . Subjects condition possibly affect drug absorption . Subjects malignancy exception adequately treat basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>end-stage renal disease</keyword>
</DOC>